E6AP promotes prostate cancer by reducing p27 expression
Metrics: PDF 1143 views | HTML 2252 views | ?
Dinesh Raghu1,2, Piotr Jan Paul1,2, Twishi Gulati1,2, Siddhartha Deb3, Christine Khoo4, Andrea Russo5, Enzo Gallo5, Giovanni Blandino6, Ai-Leen Chan2,11, Elena Takano4, Shahneen K. Sandhu7, Stephen B. Fox4, Scott Williams8, Sue Haupt1,2, Cristina Gamell1,2,* and Ygal Haupt1,2,9,10,*
1The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia
2Tumor Suppression Laboratory, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
3Anatpath Services Pty Ltd, Gardenvale, Victoria, Australia
4Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
5Department of Surgical Pathology, Regina Elena Cancer Institute, Rome, Italy
6Oncogenomic and Epigenetic Unit, Italian National Cancer Institute, Rome, Italy
7Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
8Division of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
9Department of Biochemistry and Molecular Biology, Monash University, Melbourne, Victoria, Australia
10Department of Pathology, The University of Melbourne, Melbourne, Victoria, Australia
11Current address: Australian Regenerative Medicine Institute, Monash University, Melbourne, Victoria, Australia
*Both authors have shared co-senior authorship
Ygal Haupt, email: firstname.lastname@example.org
Keywords: prostate cancer, E6AP, p27, E2F1, tumor suppression
Received: February 07, 2017 Accepted: March 16, 2017 Published: April 19, 2017
Prostate cancer (PC) is the most common cancer in men. Elevated levels of E3 ligase, E6-Associated Protein (E6AP) were previously linked to PC, consistent with increased protein expression in a subset of PC patients. In cancers, irregular E3 ligase activity drives proteasomal degradation of tumor suppressor proteins. Accordingly, E3 ligase inhibitors define a rational therapy to restore tumor suppression. The relevant tumor suppressors targeted by E6AP in PC are yet to be fully identified. In this study we show that p27, a key cell cycle regulator, is a target of E6AP in PC. Down regulation of E6AP increases p27 expression and enhances its nuclear accumulation in PC. We demonstrate that E6AP regulates p27 expression by inhibiting its transcription in an E2F1-dependent manner. Concomitant knockdown of E6AP and p27 partially restores PC cell growth, supporting the contribution of p27 to the overall effect of E6AP on prostate tumorigenesis. Overall, we unravelled the E6AP-p27 axis as a new promoter of PC, exposing an attractive target for therapy through the restoration of tumor suppression.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.